[go: up one dir, main page]

WO2001034184A3 - Methods and compositions for protection against bovine herpesvirus 1 - Google Patents

Methods and compositions for protection against bovine herpesvirus 1 Download PDF

Info

Publication number
WO2001034184A3
WO2001034184A3 PCT/US2000/030359 US0030359W WO0134184A3 WO 2001034184 A3 WO2001034184 A3 WO 2001034184A3 US 0030359 W US0030359 W US 0030359W WO 0134184 A3 WO0134184 A3 WO 0134184A3
Authority
WO
WIPO (PCT)
Prior art keywords
heat shock
shock protein
bovine herpesvirus
compositions
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2000/030359
Other languages
French (fr)
Other versions
WO2001034184A2 (en
Inventor
Subramaniam Srikumaran
Manjula Navaratnam
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Nebraska Lincoln
University of Nebraska System
Original Assignee
University of Nebraska Lincoln
University of Nebraska System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Nebraska Lincoln, University of Nebraska System filed Critical University of Nebraska Lincoln
Priority to AU15828/01A priority Critical patent/AU1582801A/en
Publication of WO2001034184A2 publication Critical patent/WO2001034184A2/en
Publication of WO2001034184A3 publication Critical patent/WO2001034184A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6043—Heat shock proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/622—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier non-covalent binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates to methods and compositions for eliciting an immune response against bovine herpesvirus 1 epitopes. The methods comprise combining at least one heat shock protein with at least one bovine herpesvirus 1 epitope to form a purified epitope/heat shock protein complex and administration of an immune system stimulating amount of the purified epitope/heat shock protein complex. The compositions comprise, a purified epitope/heat shock protein complex comprising at least one bovine herpesvirus 1 epitope complexed with at least one heat shock protein, and a pharmaceutically acceptable carrier, diluent or excipient.
PCT/US2000/030359 1999-11-05 2000-11-03 Methods and compositions for protection against bovine herpesvirus 1 Ceased WO2001034184A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU15828/01A AU1582801A (en) 1999-11-05 2000-11-03 Methods and compositions for protection against bovine herpesvirus

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16372599P 1999-11-05 1999-11-05
US60/163,725 1999-11-05

Publications (2)

Publication Number Publication Date
WO2001034184A2 WO2001034184A2 (en) 2001-05-17
WO2001034184A3 true WO2001034184A3 (en) 2002-03-07

Family

ID=22591305

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/030359 Ceased WO2001034184A2 (en) 1999-11-05 2000-11-03 Methods and compositions for protection against bovine herpesvirus 1

Country Status (2)

Country Link
AU (1) AU1582801A (en)
WO (1) WO2001034184A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001257087A1 (en) * 2000-04-17 2001-10-30 Mojave Therapeutics Inc. Heat shock protein-based antiviral vaccines
AU2002239462A1 (en) * 2000-11-03 2002-06-03 The Board Of Regents Of The University Of Nebraska Compositions for protection against bovine viral diseases
CA2728363C (en) 2008-06-26 2019-02-19 Orphazyme Aps Use of hsp70 as a regulator of enzymatic activity
PL2646044T3 (en) 2010-11-30 2020-03-31 Orphazyme A/S Methods for increasing intracellular activity of hsp70
BRPI1101186B1 (en) * 2011-12-29 2019-06-25 Universidade Federal De Minas Gerais RECOMBINANT PROTEINS, POLYNUCLEOTES AND VACCINES AGAINST BOVINE HERPESVIRUS
JP6678676B2 (en) 2014-09-15 2020-04-08 オーファザイム エー／エス Arimoclomol formulation
US10898476B2 (en) 2016-04-13 2021-01-26 Orphazyme A/S Heat shock proteins and cholesterol homeostasis
BR112018070653A2 (en) 2016-04-29 2019-02-05 Orphazyme As active pharmaceutical ingredient and composition
AU2021380947C1 (en) 2020-11-19 2025-02-20 Zevra Denmark A/S Processes for preparing arimoclomol citrate and intermediates thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5151267A (en) * 1988-07-15 1992-09-29 University Of Saskatchewan Bovine herpesvirus type 1 polypeptides and vaccines
WO1998034641A1 (en) * 1997-02-07 1998-08-13 Fordham University Prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases with heat shock/stress protein-peptide complexes

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5151267A (en) * 1988-07-15 1992-09-29 University Of Saskatchewan Bovine herpesvirus type 1 polypeptides and vaccines
WO1998034641A1 (en) * 1997-02-07 1998-08-13 Fordham University Prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases with heat shock/stress protein-peptide complexes

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
NIELAND T J F ET AL: "ISOLATION OF AN IMMUNODOMINANT VIRAL PEPTIDE THAT IS ENDOGENOUSLY BOUND TO THE STRESS PROTEIN GP96/GRP94", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA,US,NATIONAL ACADEMY OF SCIENCE. WASHINGTON, vol. 93, 1 June 1996 (1996-06-01), pages 6135 - 6139, XP002912527, ISSN: 0027-8424 *
SCHILD HANSJORG ET AL: "Stress proteins and immunity mediated by cytotoxic T lymphocytes.", CURRENT OPINION IN IMMUNOLOGY, vol. 11, no. 1, February 1999 (1999-02-01), pages 109 - 113, XP002164414, ISSN: 0952-7915 *
ZATECHKA D S ET AL: "Identification of murine cytotoxic T-lymphocyte epitopes of bovine herpesvirus 1", VACCINE,GB,BUTTERWORTH SCIENTIFIC. GUILDFORD, vol. 17, no. 7-8, 26 February 1999 (1999-02-26), pages 686 - 694, XP004154807, ISSN: 0264-410X *

Also Published As

Publication number Publication date
WO2001034184A2 (en) 2001-05-17
AU1582801A (en) 2001-06-06

Similar Documents

Publication Publication Date Title
WO2000018351A3 (en) Aglyco products and methods of use
WO1999055730A3 (en) Polyepitope carrier protein
CA2172507A1 (en) Methods and compositions for microencapsulation of antigens for use as vaccines
WO2000062800A3 (en) Adjuvant composition comprising saponin and an immunostimulatory oligonucleotide
CA2096529A1 (en) Recombinant avirulent salmonella antifertility vaccines
IL136215A0 (en) Spheroids, preparation method and pharmaceutical compositions
EP2275126A3 (en) Protein-based streptococcus pneumoniae vaccines
EP0955059A3 (en) Vaccines containing a saponin and a sterol
WO2000076540A3 (en) Streptococcus pneumoniae proteins and vaccines
WO2001005355A3 (en) Formulations for il-11
EP0745387A3 (en) Adjuvants for viral vaccines
ZA936629B (en) Potentiation of immunogenic response
EP0866133A3 (en) A group b streptococcus vaccine
WO1996009805A3 (en) Chitosan induced immunopotentiation
WO2001034184A3 (en) Methods and compositions for protection against bovine herpesvirus 1
AU1170399A (en) Spheroids containing tiagabine, preparation process and pharmaceutical comp ositions
MY129437A (en) Drug formulation having controlled release of active compound
WO2001079259A8 (en) Javelinization of protein antigens to heat shock proteins
WO1994010317A3 (en) Conjugate vaccine against group b streptococcus
WO1991015512A3 (en) Hiv envelope polypeptides
WO2002041921A3 (en) Compositions for protection against bovine viral diseases
WO2002034287A3 (en) Therapeutic vaccine formulations containing chitosan
ZA200109516B (en) Method for preparing dual virally inactivated immune globulin for intravenous administration.
CA2100591A1 (en) Avirulent anti-rabies vaccine
CA2238278A1 (en) Antigenic protein originating in malassezia

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase